Novo Nordisk plans to invest an additional $22 million in its finished-products manufacturing plant in North Carolina, USA. The move comes 10 months after the company unveiled plans for a $65-million expansion there. This is the company’s fourth expansion at the site since 2010.

Novo Nordisk’s manufacturing facility in Clayton, NC, is responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines. The new site, which is scheduled to be operational in 2020, is situated adjacent to Novo Nordisk’s current production site  responsible for formulation, filling and packaging of diabetes medicines. That plant also assembles and packages the company’s prefilled insulin devices for the US market.